Histiocytic Neoplasms, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology

View More View Less
  • 1 Mayo Clinic Cancer Center;
  • | 2 Dana-Farber/Brigham and Women's Cancer Center | Massachusetts General Hospital Cancer Center;
  • | 3 The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute;
  • | 4 Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute Cleveland Clinic Children's Hospital;
  • | 5 UT Southwestern Simmons Comprehensive Cancer Center;
  • | 6 St. Jude Children's Research Hospital/The University of Tennessee Health Science Center;
  • | 7 Fred & Pamela Buffett Cancer Center;
  • | 8 Memorial Sloan Kettering Cancer Center;
  • | 9 Yale Cancer Center/Smilow Cancer Hospital;
  • | 10 UC San Diego Moores Cancer Center;
  • | 11 O'Neal Comprehensive Cancer Center at UAB;
  • | 12 Stanford Cancer Institute;
  • | 13 Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance;
  • | 14 Roswell Park Comprehensive Cancer Center;
  • | 15 Abramson Cancer Center at the University of Pennsylvania;
  • | 16 The University of Texas MD Anderson Cancer Center;
  • | 17 Robert H. Lurie Comprehensive Cancer Center of Northwestern University;
  • | 18 Vanderbilt-Ingram Cancer Center;
  • | 19 UCLA Jonsson Comprehensive Cancer Center;
  • | 20 Duke Cancer Institute;
  • | 21 Huntsman Cancer Institute at the University of Utah;
  • | 22 University of Michigan Rogel Cancer Center;
  • | 23 Moffitt Cancer Center; and
  • | 24 National Comprehensive Cancer Network

Histiocytic neoplasms are rare hematologic disorders accounting for less than 1% of cancers of the soft tissue and lymph nodes. Clinical presentation and prognosis of these disorders can be highly variable, leading to challenges for diagnosis and optimal management of these patients. Treatment often consists of systemic therapy, and recent studies support use of targeted therapies for patients with these disorders. Observation (“watch and wait”) may be sufficient for select patients with mild disease. These NCCN Guidelines for Histiocytic Neoplasms include recommendations for diagnosis and treatment of adults with the most common histiocytic disorders: Langerhans cell histiocytosis, Erdheim-Chester disease, and Rosai-Dorfman disease.

Individual Disclosures for the NCCN Histiocytic Neoplasms Panel

T1

  • 1.

    Emile JF, Abla O, Fraitag S, et al. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood 2016;127:26722681.

  • 2.

    Durham BH. Molecular characterization of the histiocytoses: neoplasia of dendritic cells and macrophages. Semin Cell Dev Biol 2019;86:6276.

  • 3.

    Goyal G, Young JR, Koster MJ, et al. The Mayo Clinic Histiocytosis Working Group consensus statement for the diagnosis and evaluation of adult patients with histiocytic neoplasms: Erdheim-Chester disease, Langerhans cell histiocytosis, and Rosai-Dorfman disease. Mayo Clin Proc 2019;94:20542071.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 4.

    Writing Group of the Histiocyte Society. Histiocytosis syndromes in children. Lancet 1987;1:208209.

  • 5.

    Badalian-Very G, Vergilio JA, Degar BA, et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood 2010;116:19191923.

  • 6.

    Haroche J, Charlotte F, Arnaud L, et al. High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood 2012;120:27002703.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 7.

    Emile JF, Diamond EL, Hélias-Rodzewicz Z, et al. Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease. Blood 2014;124:30163019.

  • 8.

    Diamond EL, Durham BH, Haroche J, et al. Diverse and targetable kinase alterations drive histiocytic neoplasms. Cancer Discov 2016;6:154165.

  • 9.

    Chang KTE, Tay AZE, Kuick CH, et al. ALK-positive histiocytosis: an expanded clinicopathologic spectrum and frequent presence of KIF5B-ALK fusion. Mod Pathol 2019;32:598608.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    Guyot-Goubin A, Donadieu J, Barkaoui M, et al. Descriptive epidemiology of childhood Langerhans cell histiocytosis in France, 2000-2004. Pediatr Blood Cancer 2008;51:7175.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11.

    Stålemark H, Laurencikas E, Karis J, et al. Incidence of Langerhans cell histiocytosis in children: a population-based study. Pediatr Blood Cancer 2008;51:7681.

  • 12.

    Haroche J, Cohen-Aubart F, Rollins BJ, et al. Histiocytoses: emerging neoplasia behind inflammation. Lancet Oncol 2017;18:e113e125.

  • 13.

    Vassallo R, Ryu JH, Schroeder DR, et al. Clinical outcomes of pulmonary Langerhans’-cell histiocytosis in adults. N Engl J Med 2002;346:484490.

  • 14.

    Girschikofsky M, Arico M, Castillo D, et al. Management of adult patients with Langerhans cell histiocytosis: recommendations from an expert panel on behalf of Euro-Histio-Net. Orphanet J Rare Dis 2013;8:72.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 15.

    Tazi A. Adult pulmonary Langerhans’ cell histiocytosis. Eur Respir J 2006;27:12721285.

  • 16.

    Makras P, Terpos E, Kanakis G, et al. Reduced bone mineral density in adult patients with Langerhans cell histiocytosis. Pediatr Blood Cancer 2012;58:819822.

  • 17.

    Rigaud C, Barkaoui MA, Thomas C, et al. Langerhans cell histiocytosis: therapeutic strategy and outcome in a 30-year nationwide cohort of 1478 patients under 18 years of age. Br J Haematol 2016;174:887898.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 18.

    Aricò M, Girschikofsky M, Généreau T, et al. Langerhans cell histiocytosis in adults. Report from the International Registry of the Histiocyte Society. Eur J Cancer 2003;39:23412348.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 19.

    Ma J, Laird JH, Chau KW, et al. Langerhans cell histiocytosis in adults is associated with a high prevalence of hematologic and solid malignancies. Cancer Med 2019;8:5866.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 20.

    Goyal G, Shah MV, Hook CC, et al. Adult disseminated Langerhans cell histiocytosis: incidence, racial disparities and long-term outcomes. Br J Haematol 2018;182:579581.

  • 21.

    Grois N, Fahrner B, Arceci RJ, et al. Central nervous system disease in Langerhans cell histiocytosis. J Pediatr 2010;156:873881.e1.

  • 22.

    Héritier S, Barkaoui MA, Miron J, et al. Incidence and risk factors for clinical neurodegenerative Langerhans cell histiocytosis: a longitudinal cohort study. Br J Haematol 2018;183:608617.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 23.

    Willman CL, Busque L, Griffith BB, et al. Langerhans’-cell histiocytosis (histiocytosis X)--a clonal proliferative disease. N Engl J Med 1994;331:154160.

  • 24.

    Allen CE, Merad M, McClain KL. Langerhans-cell histiocytosis. N Engl J Med 2018;379:856868.

  • 25.

    Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016;127:23752390.

  • 26.

    Phillips M, Allen C, Gerson P, et al. Comparison of FDG-PET scans to conventional radiography and bone scans in management of Langerhans cell histiocytosis. Pediatr Blood Cancer 2009;52:97101.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 27.

    Albano D, Bosio G, Giubbini R, et al. Role of 18F-FDG PET/CT in patients affected by Langerhans cell histiocytosis. Jpn J Radiol 2017;35:574583.

  • 28.

    Obert J, Vercellino L, Van Der Gucht A, et al. 18F-fluorodeoxyglucose positron emission tomography-computed tomography in the management of adult multisystem Langerhans cell histiocytosis. Eur J Nucl Med Mol Imaging 2017;44:598610.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 29.

    Thingujam B, Yu YT, Lee JY, et al. Tumour-stage mycosis fungoides initially misdiagnosed as Langerhans cell histiocytosis. Pathology 2020;52:593596.

  • 30.

    Lamiaux M, Scalbert C, Lepesant P, et al. Severe skin toxicity with organ damage under the combination of targeted therapy following immunotherapy in metastatic melanoma. Melanoma Res 2018;28:451457.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 31.

    Diamond EL, Durham BH, Ulaner GA, et al. Efficacy of MEK inhibition in patients with histiocytic neoplasms. Nature 2019;567:521524.

  • 32.

    Urner-Bloch U, Urner M, Jaberg-Bentele N, et al. MEK inhibitor-associated retinopathy (MEKAR) in metastatic melanoma: long-term ophthalmic effects. Eur J Cancer 2016;65:130138.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 33.

    Collin M, Bigley V, McClain KL, et al. Cell(s) of origin of Langerhans cell histiocytosis. Hematol Oncol Clin North Am 2015;29:825838.

  • 34.

    Grois N, Prayer D, Prosch H, et al. Neuropathology of CNS disease in Langerhans cell histiocytosis. Brain 2005;128:829838.

  • 35.

    Chatterjee D, Vishwajeet V, Saikia UN, et al. CyclinD1 is useful to differentiate Langerhans cell histiocytosis from reactive Langerhans cells. Am J Dermatopathol 2019;41:188192.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 36.

    Shanmugam V, Craig JW, Hornick JL, et al. Cyclin D1 is expressed in neoplastic cells of Langerhans cell histiocytosis but not reactive Langerhans cell proliferations. Am J Surg Pathol 2017;41:13901396.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 37.

    Berres ML, Merad M, Allen CE. Progress in understanding the pathogenesis of Langerhans cell histiocytosis: back to Histiocytosis X? Br J Haematol 2015;169:313.

  • 38.

    Rollins BJ. Genomic alterations in Langerhans cell histiocytosis. Hematol Oncol Clin North Am 2015;29:839851.

  • 39.

    Berres ML, Lim KP, Peters T, et al. BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups. J Exp Med 2014;211:669683.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 40.

    Héritier S, Emile JF, Barkaoui MA, et al. BRAF mutation correlates with high-risk Langerhans cell histiocytosis and increased resistance to first-line therapy. J Clin Oncol 2016;34:30233030.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 41.

    Satoh T, Smith A, Sarde A, et al. B-RAF mutant alleles associated with Langerhans cell histiocytosis, a granulomatous pediatric disease. PLoS One 2012;7:e33891.

  • 42.

    Brown NA, Furtado LV, Betz BL, et al. High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis. Blood 2014;124:16551658.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 43.

    Hervier B, Haroche J, Arnaud L, et al. Association of both Langerhans cell histiocytosis and Erdheim-Chester disease linked to the BRAFV600E mutation. Blood 2014;124:11191126.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 44.

    Chakraborty R, Hampton OA, Shen X, et al. Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis. Blood 2014;124:30073015.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 45.

    Goyal G, Heaney ML, Collin M, et al. Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era. Blood 2020;135:19291945.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 46.

    Durham BH, Lopez Rodrigo E, Picarsic J, et al. Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms. Nat Med 2019;25:18391842.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 47.

    Fisher KE, Cohen C, Siddiqui MT, et al. Accurate detection of BRAF p.V600E mutations in challenging melanoma specimens requires stringent immunohistochemistry scoring criteria or sensitive molecular assays. Hum Pathol 2014;45:22812293.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 48.

    Phan DAT, Phung GB, Duong TT, et al. The value of BRAF VE1 immunoexpression in pediatric Langerhans cell histiocytosis [published online December 9, 2020]. Fetal Pediatr Pathol, doi: https://doi.org/10.1080/15513815.2020.1857483

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 49.

    Ballester LY, Cantu MD, Lim KPH, et al. The use of BRAF V600E mutation-specific immunohistochemistry in pediatric Langerhans cell histiocytosis. Hematol Oncol 2018;36:307315.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 50.

    Allen CE, Ladisch S, McClain KL. How I treat Langerhans cell histiocytosis. Blood 2015;126:2635.

  • 51.

    Laird J, Ma J, Chau K, et al. Outcome after radiation therapy for Langerhans cell histiocytosis is dependent on site of involvement. Int J Radiat Oncol Biol Phys 2018;100:670678.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 52.

    Heyd R, Strassmann G, Donnerstag F, et al. [Radiotherapy in Langerhans-cell histiocytosis. 2 case reports and review of the literature]. Rontgenpraxis 2000;53:5161.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 53.

    Sakai H, Ibe M, Takahashi H, et al. Satisfactory remission achieved by PUVA therapy in Langerhans cell histocytosis in an elderly patient. J Dermatol 1996;23:4246.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 54.

    Imafuku S, Shibata S, Tashiro A, et al. Cutaneous Langerhans cell histiocytosis in an elderly man successfully treated with narrowband ultraviolet B. Br J Dermatol 2007;157:12771279.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 55.

    Hoeger PH, Nanduri VR, Harper JI, et al. Long term follow up of topical mustine treatment for cutaneous langerhans cell histiocytosis. Arch Dis Child 2000;82:483487.

  • 56.

    Kaneshima A, Yamaguchi S, Miyagi T, et al. Extracellular signal-regulated kinase activation of self-healing Langerhans cell histiocytosis: a case report. J Dermatol 2019;46:812815.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 57.

    Simko SJ, Garmezy B, Abhyankar H, et al. Differentiating skin-limited and multisystem Langerhans cell histiocytosis. J Pediatr 2014;165:990996.

  • 58.

    Schönfeld N, Frank W, Wenig S, et al. Clinical and radiologic features, lung function and therapeutic results in pulmonary histiocytosis X. Respiration 1993;60:3844.

  • 59.

    Chellapandian D, Makras P, Kaltsas G, et al. Bisphosphonates in Langerhans cell histiocytosis: an international retrospective case series. Mediterr J Hematol Infect Dis 2016;8:e2016033.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 60.

    Montella L, Merola C, Merola G, et al. Zoledronic acid in treatment of bone lesions by Langerhans cell histiocytosis. J Bone Miner Metab 2009;27:110113.

  • 61.

    De Benedittis D, Mohamed S, Rizzo L, et al. Indomethacin is an effective treatment in adults and children with bone Langerhans cell histiocytosis (LCH). Br J Haematol 2020;191:e109e113.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 62.

    Cantu MA, Lupo PJ, Bilgi M, et al. Optimal therapy for adults with Langerhans cell histiocytosis bone lesions. PLoS One 2012;7:e43257.

  • 63.

    Saven A, Burian C. Cladribine activity in adult Langerhans-cell histiocytosis. Blood 1999;93:41254130.

  • 64.

    Goyal G, Abeykoon JP, Hu M, et al. Single-agent cladribine as an effective front-line therapy for adults with Langerhans cell histiocytosis. Am J Hematol 2021;96:E146E150.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 65.

    Simko SJ, Tran HD, Jones J, et al. Clofarabine salvage therapy in refractory multifocal histiocytic disorders, including Langerhans cell histiocytosis, juvenile xanthogranuloma and Rosai-Dorfman disease. Pediatr Blood Cancer 2014;61:479487.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 66.

    Cao XX, Li J, Zhao AL, et al. Methotrexate and cytarabine for adult patients with newly diagnosed Langerhans cell histiocytosis: a single arm, single center, prospective phase 2 study. Am J Hematol 2020;95:E235E238.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 67.

    Miao HL, Zhao AL, Duan MH, et al. Clinical presentation and prognostic analysis of adult patients with Langerhans cell histiocytosis with pulmonary involvement. BMC Cancer 2020;20:911.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 68.

    Ho P, Smith C. High-dose methotrexate for the treatment of relapsed central nervous system Erdheim-Chester disease. Case Rep Hematol 2014;2014:269359.

  • 69.

    Ehrhardt MJ, Karst J, Donohoue PA, et al. Recognition and treatment of concurrent active and neurodegenerative Langerhans cell histiocytosis: a case report. J Pediatr Hematol Oncol 2015;37:e37e40.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 70.

    Allen CE, Flores R, Rauch R, et al. Neurodegenerative central nervous system Langerhans cell histiocytosis and coincident hydrocephalus treated with vincristine/cytosine arabinoside. Pediatr Blood Cancer 2010;54:416423.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 71.

    Zinn DJ, Grimes AB, Lin H, et al. Hydroxyurea: a new old therapy for Langerhans cell histiocytosis. Blood 2016;128:24622465.

  • 72.

    Womer RB, Anunciato KR, Chehrenama M. Oral methotrexate and alternate-day prednisone for low-risk Langerhans cell histiocytosis. Med Pediatr Oncol 1995;25:7073.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 73.

    McClain KL, Kozinetz CA. A phase II trial using thalidomide for Langerhans cell histiocytosis. Pediatr Blood Cancer 2007;48:4449.

  • 74.

    Szturz P, Adam Z, Rehák Z, et al. Lenalidomide proved effective in multisystem Langerhans cell histiocytosis. Acta Oncol 2012;51:412415.

  • 75.

    Hyman DM, Puzanov I, Subbiah V, et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med 2015;373:726736.

  • 76.

    Diamond EL, Subbiah V, Lockhart AC, et al. Vemurafenib for BRAF V600-mutant Erdheim-Chester disease and Langerhans cell histiocytosis: analysis of data from the histology-independent, phase 2, open-label VE-BASKET Study. JAMA Oncol 2018;4:384388.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 77.

    Hazim AZ, Ruan GJ, Ravindran A, et al. Efficacy of BRAF-inhibitor therapy in BRAF(V600E)-mutated adult Langerhans cell histiocytosis. Oncologist 2020;25:10011004.

  • 78.

    Lorillon G, Jouenne F, Baroudjian B, et al. Response to trametinib of a pulmonary Langerhans cell histiocytosis harboring a MAP2K1 deletion. Am J Respir Crit Care Med 2018;198:675678.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 79.

    Messinger YH, Bostrom BC, Olson DR, et al. Langerhans cell histiocytosis with BRAF p.N486_P490del or MAP2K1 p.K57_G61del treated by the MEK inhibitor trametinib. Pediatr Blood Cancer 2020;67:e28712.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 80.

    Papapanagiotou M, Griewank KG, Hillen U, et al. Trametinib-induced remission of an MEK1-mutated Langerhans cell histiocytosis [published online May 18, 2017]. JCO Precis Oncol, doi: https://doi.org/10.1200/PO.16.00070

    • Search Google Scholar
    • Export Citation
  • 81.

    Awada G, Seremet T, Fostier K, et al. Long-term disease control of Langerhans cell histiocytosis using combined BRAF and MEK inhibition. Blood Adv 2018;2:21562158.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 82.

    Taylor J, Pavlick D, Yoshimi A, et al. Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies. J Clin Invest 2018;128:38193825.

  • 83.

    Drilon A, Laetsch TW, Kummar S, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med 2018;378:731739.

  • 84.

    Doebele RC, Drilon A, Paz-Ares L, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol 2020;21:271282.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 85.

    van Bommel EFH, van der Zijden MA, Smak Gregoor PJH, et al. Sirolimus monotherapy for Erdheim-Chester disease. Acta Oncol 2019;58:901905.

  • 86.

    Diamond EL, Dagna L, Hyman DM, et al. Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease. Blood 2014;124:483492.

  • 87.

    Haroche J, Cluzel P, Toledano D, et al. Images in cardiovascular medicine. Cardiac involvement in Erdheim-Chester disease: magnetic resonance and computed tomographic scan imaging in a monocentric series of 37 patients. Circulation 2009;119:e597e598.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 88.

    Brun AL, Touitou-Gottenberg D, Haroche J, et al. Erdheim-Chester disease: CT findings of thoracic involvement. Eur Radiol 2010;20:25792587.

  • 89.

    Gianfreda D, Palumbo AA, Rossi E, et al. Cardiac involvement in Erdheim-Chester disease: an MRI study. Blood 2016;128:24682471.

  • 90.

    Haroche J, Amoura Z, Dion E, et al. Cardiovascular involvement, an overlooked feature of Erdheim-Chester disease: report of 6 new cases and a literature review. Medicine (Baltimore) 2004;83:371392.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 91.

    Arnaud L, Pierre I, Beigelman-Aubry C, et al. Pulmonary involvement in Erdheim-Chester disease: a single-center study of thirty-four patients and a review of the literature. Arthritis Rheum 2010;62:35043512.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 92.

    Estrada-Veras JI, O’Brien KJ, Boyd LC, et al. The clinical spectrum of Erdheim-Chester disease: an observational cohort study. Blood Adv 2017;1:357366.

  • 93.

    Serratrice J, Granel B, De Roux C, et al. “Coated aorta”: a new sign of Erdheim-Chester disease. J Rheumatol 2000;27:15501553.

  • 94.

    Cavalli G, Guglielmi B, Berti A, et al. The multifaceted clinical presentations and manifestations of Erdheim-Chester disease: comprehensive review of the literature and of 10 new cases. Ann Rheum Dis 2013;72:16911695.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 95.

    Villatoro-Villar M, Bold MS, Warrington KJ, et al. Arterial involvement in Erdheim-Chester disease: A retrospective cohort study. Medicine (Baltimore) 2018;97:e13452.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 96.

    Haroche J, Arnaud L, Amoura Z. Erdheim-Chester disease. Curr Opin Rheumatol 2012;24:5359.

  • 97.

    Dion E, Graef C, Haroche J, et al. Imaging of thoracoabdominal involvement in Erdheim-Chester disease. AJR Am J Roentgenol 2004;183:12531260.

  • 98.

    Mazor RD, Manevich-Mazor M, Shoenfeld Y. Erdheim-Chester Disease: a comprehensive review of the literature. Orphanet J Rare Dis 2013;8:137.

  • 99.

    Parks NE, Goyal G, Go RS, et al. Neuroradiologic manifestations of Erdheim-Chester disease. Neurol Clin Pract 2018;8:1520.

  • 100.

    Arnaud L, Hervier B, Néel A, et al. CNS involvement and treatment with interferon-α are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients. Blood 2011;117:27782782.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 101.

    Courtillot C, Laugier Robiolle S, Cohen Aubart F, et al. Endocrine manifestations in a monocentric cohort of 64 patients with Erdheim-Chester disease. J Clin Endocrinol Metab 2016;101:305313.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 102.

    Papo M, Diamond EL, Cohen-Aubart F, et al. High prevalence of myeloid neoplasms in adults with non-Langerhans cell histiocytosis. Blood 2017;130:10071013.

  • 103.

    Goyal G, Ravindran A, Liu Y, et al. Bone marrow findings in Erdheim-Chester disease: increased prevalence of chronic myeloid neoplasms. Haematologica 2020;105:e84e86.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 104.

    Tzankov A, Kremer M, Leguit R, et al. Histiocytic cell neoplasms involving the bone marrow: summary of the workshop cases submitted to the 18th Meeting of the European Association for Haematopathology (EAHP) organized by the European Bone Marrow Working Group, Basel 2016. Ann Hematol 2018;97:21172128.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 105.

    Ozkaya N, Rosenblum MK, Durham BH, et al. The histopathology of Erdheim-Chester disease: a comprehensive review of a molecularly characterized cohort. Mod Pathol 2018;31:581597.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 106.

    Janku F, Diamond EL, Goodman AM, et al. Molecular profiling of tumor tissue and plasma cell-free DNA from patients with non-Langerhans cell histiocytosis. Mol Cancer Ther 2019;18:11491157.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 107.

    Razanamahery J, Diamond EL, Cohen-Aubart F, et al. Erdheim-Chester disease with concomitant Rosai-Dorfman like lesions: a distinct entity mainly driven by MAP2K1. Haematologica 2020;105:e5e8.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 108.

    Ruan GJ, Hazim A, Abeykoon JP, et al. Low-dose vemurafenib monotherapy in BRAFV600E -mutated Erdheim-Chester disease. Leuk Lymphoma 2020;61:27332737.

  • 109.

    Cohen Aubart F, Emile JF, Carrat F, et al. Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study). Blood 2017;130:13771380.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 110.

    Bhatia A, Ulaner G, Rampal R, et al. Single-agent dabrafenib for BRAFV600E-mutated histiocytosis. Haematologica 2018;103:e177e180.

  • 111.

    Janku F, Patel H, Raghavan VK, et al. MEK inhibition with trametinib in patients with non-Langerhans histiocytosis irrespective of BRAF mutation status. Blood 2019;134(Suppl_1):2319.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 112.

    Haroche J, Amoura Z, Trad SG, et al. Variability in the efficacy of interferon-alpha in Erdheim-Chester disease by patient and site of involvement: results in eight patients. Arthritis Rheum 2006;54:33303336.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 113.

    Hervier B, Arnaud L, Charlotte F, et al. Treatment of Erdheim-Chester disease with long-term high-dose interferon-α. Semin Arthritis Rheum 2012;41:907913.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 114.

    Esmaeli B, Ahmadi A, Tang R, et al. Interferon therapy for orbital infiltration secondary to Erdheim-Chester disease. Am J Ophthalmol 2001;132:945947.

  • 115.

    Suzuki HI, Hosoya N, Miyagawa K, et al. Erdheim-Chester disease: multisystem involvement and management with interferon-alpha. Leuk Res 2010;34:e21e24.

  • 116.

    Goyal G, Shah MV, Call TG, et al. Clinical and radiologic responses to cladribine for the treatment of Erdheim-Chester disease. JAMA Oncol 2017;3:12531256.

  • 117.

    Gianfreda D, Nicastro M, Galetti M, et al. Sirolimus plus prednisone for Erdheim-Chester disease: an open-label trial. Blood 2015;126:11631171.

  • 118.

    Goyal G, Shah MV, Call TG, et al. Clinical and radiological responses to oral methotrexate alone or in combination with other agents in Erdheim-Chester disease. Blood Cancer J 2017;7:647.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 119.

    Cohen-Aubart F, Maksud P, Saadoun D, et al. Variability in the efficacy of the IL1 receptor antagonist anakinra for treating Erdheim-Chester disease. Blood 2016;127:15091512.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 120.

    Goyal G, Shah MV, Call TG, et al. Efficacy of biological agents in the treatment of Erdheim-Chester disease. Br J Haematol 2018;183:520524.

  • 121.

    Abla O, Jacobsen E, Picarsic J, et al. Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease. Blood 2018;131:28772890.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 122.

    Goyal G, Ravindran A, Young JR, et al. Clinicopathological features, treatment approaches, and outcomes in Rosai-Dorfman disease. Haematologica 2020;105:348357.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 123.

    Juskevicius R, Finley JL. Rosai-Dorfman disease of the parotid gland: cytologic and histopathologic findings with immunohistochemical correlation. Arch Pathol Lab Med 2001;125:13481350.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 124.

    Sandoval-Sus JD, Sandoval-Leon AC, Chapman JR, et al. Rosai-Dorfman disease of the central nervous system: report of 6 cases and review of the literature. Medicine (Baltimore) 2014;93:165175.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 125.

    Andriko JA, Morrison A, Colegial CH, et al. Rosai-Dorfman disease isolated to the central nervous system: a report of 11 cases. Mod Pathol 2001;14:172178.

  • 126.

    Molho-Pessach V, Ramot Y, Camille F, et al. H syndrome: the first 79 patients. J Am Acad Dermatol 2014;70:8088.

  • 127.

    Mahajan S, Nakajima R, Yabe M, et al. Rosai-Dorfman disease-utility of 18F-FDG PET/CT for initial evaluation and follow-up. Clin Nucl Med 2020;45:e260e266.

  • 128.

    Cartin-Ceba R, Golbin JM, Yi ES, et al. Intrathoracic manifestations of Rosai-Dorfman disease. Respir Med 2010;104:13441349.

  • 129.

    Baraban E, Sadigh S, Rosenbaum J, et al. Cyclin D1 expression and novel mutational findings in Rosai-Dorfman disease. Br J Haematol 2019;186:837844.

  • 130.

    Deshpande V, Zen Y, Chan JK, et al. Consensus statement on the pathology of IgG4-related disease. Mod Pathol 2012;25:11811192.

  • 131.

    Garces S, Medeiros LJ, Patel KP, et al. Mutually exclusive recurrent KRAS and MAP2K1 mutations in Rosai-Dorfman disease. Mod Pathol 2017;30:13671377.

  • 132.

    Maklad AM, Bayoumi Y, Tunio M, et al. Steroid-resistant extranodal Rosai-Dorfman disease of cheek mass and ptosis treated with radiation therapy. Case Rep Hematol 2013;2013:428297.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 133.

    Toguri D, Louie AV, Rizkalla K, et al. Radiotherapy for steroid-resistant laryngeal Rosai-Dorfman disease. Curr Oncol 2011;18:e158e162.

  • 134.

    Namoglu EC, Hughes ME, Plastaras JP, et al. Management and outcomes of sinus histiocytosis with massive lymphadenopathy (Rosai Dorfman Disease). Leuk Lymphoma 2020;61:905911.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 135.

    Nasseri E, Belisle A, Funaro D. Rosai-Dorfman disease treated with methotrexate and low-dose prednisone: case report and review of the literature. J Cutan Med Surg 2012;16:281285.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 136.

    Wang W, Sun J, Zhang W, et al. Successful treatment of intracranial Rosai-Dorfman disease with cytarabine and dexamethasone: case report and review of literature. Ann Hematol 2020;99:11571159.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 137.

    Nadal M, Kervarrec T, Machet MC, et al. Cutaneous Rosai-Dorfman disease located on the breast: rapid effectiveness of methotrexate after failure of topical corticosteroids, acitretin and thalidomide. Acta Derm Venereol 2015;95:758759.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 138.

    Chen E, Pavlidakey P, Sami N. Rosai-Dorfman disease successfully treated with thalidomide. JAAD Case Rep 2016;2:369372.

  • 139.

    Inoue S, Onwuzurike N. Venorelbine and methotrexate for the treatment of Rosai-Dorfman disease. Pediatr Blood Cancer 2005;45:8485., author reply 86.

  • 140.

    Teachey DT, Greiner R, Seif A, et al. Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome. Br J Haematol 2009;145:101106.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 141.

    Cooper SL, Arceci RJ, Gamper CJ, et al. Successful treatment of recurrent autoimmune cytopenias in the context of sinus histiocytosis with massive lymphadenopathy using sirolimus. Pediatr Blood Cancer 2016;63:358360.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 142.

    Cohen-Barak E, Rozenman D, Schafer J, et al. An unusual co-occurrence of Langerhans cell histiocytosis and Rosai-Dorfman disease: report of a case and review of the literature. Int J Dermatol 2014;53:558563.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 143.

    Moyon Q, Boussouar S, Maksud P, et al. Lung involvement in Destombes-Rosai-Dorfman disease: clinical and radiological features and response to the MEK inhibitor cobimetinib. Chest 2020;157:323333.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 144.

    Jacobsen E, Shanmugam V, Jagannathan J. Rosai-Dorfman disease with activating KRAS mutation - response to cobimetinib. N Engl J Med 2017;377:23982399.

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 877 877 877
PDF Downloads 610 610 610
EPUB Downloads 0 0 0